186 related articles for article (PubMed ID: 27166664)
1. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Azzi G; Velez M; Mathias-Machado MC
Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic approaches in chondrosarcoma.
Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
[TBL] [Abstract][Full Text] [Related]
5. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
7. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Nazeri E; Gouran Savadkoohi M; Majidzadeh-A K; Esmaeili R
Crit Rev Oncol Hematol; 2018 Nov; 131():102-109. PubMed ID: 30293700
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in chondrosarcomas - keys to targeted therapies?
Samuel AM; Costa J; Lindskog DM
Cell Oncol (Dordr); 2014 Apr; 37(2):95-105. PubMed ID: 24458248
[TBL] [Abstract][Full Text] [Related]
9. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
[TBL] [Abstract][Full Text] [Related]
10. Andrographolide Induces Cell Cycle Arrest and Apoptosis of Chondrosarcoma by Targeting TCF-1/SOX9 Axis.
Zhang HT; Yang J; Liang GH; Gao XJ; Sang Y; Gui T; Liang ZJ; Tam MS; Zha ZG
J Cell Biochem; 2017 Dec; 118(12):4575-4586. PubMed ID: 28485543
[TBL] [Abstract][Full Text] [Related]
11. [Inflammation as molecular target in chondrosarcoma].
Kalinski T
Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
[TBL] [Abstract][Full Text] [Related]
12. Update on chondrosarcomas.
Chow WA
Curr Opin Oncol; 2007 Jul; 19(4):371-6. PubMed ID: 17545802
[TBL] [Abstract][Full Text] [Related]
13. A novel benzofuran derivative, ACDB, induces apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress.
Su CM; Chen CY; Lu T; Sun Y; Li W; Huang YL; Tsai CH; Chang CS; Tang CH
Oncotarget; 2016 Dec; 7(50):83530-83543. PubMed ID: 27835579
[TBL] [Abstract][Full Text] [Related]
14. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.
Kim H; Cho Y; Kim HS; Kang D; Cheon D; Kim YJ; Chang MJ; Lee KM; Chang CB; Kang SB; Kang HG; Kim JH
Nat Commun; 2020 Oct; 11(1):5023. PubMed ID: 33024108
[TBL] [Abstract][Full Text] [Related]
15. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
[TBL] [Abstract][Full Text] [Related]
16. Chondrosarcoma: biology, genetics, and epigenetics.
Chow WA
F1000Res; 2018; 7():. PubMed ID: 30519452
[TBL] [Abstract][Full Text] [Related]
17. Biological aspects of chondrosarcoma: Leaps and hurdles.
Mery B; Espenel S; Guy JB; Rancoule C; Vallard A; Aloy MT; Rodriguez-Lafrasse C; Magné N
Crit Rev Oncol Hematol; 2018 Jun; 126():32-36. PubMed ID: 29759564
[TBL] [Abstract][Full Text] [Related]
18. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
Tarpey PS; Behjati S; Cooke SL; Van Loo P; Wedge DC; Pillay N; Marshall J; O'Meara S; Davies H; Nik-Zainal S; Beare D; Butler A; Gamble J; Hardy C; Hinton J; Jia MM; Jayakumar A; Jones D; Latimer C; Maddison M; Martin S; McLaren S; Menzies A; Mudie L; Raine K; Teague JW; Tubio JM; Halai D; Tirabosco R; Amary F; Campbell PJ; Stratton MR; Flanagan AM; Futreal PA
Nat Genet; 2013 Aug; 45(8):923-6. PubMed ID: 23770606
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic molecular targets in human chondrosarcoma.
Jamil N; Howie S; Salter DM
Int J Exp Pathol; 2010 Oct; 91(5):387-93. PubMed ID: 21078112
[TBL] [Abstract][Full Text] [Related]
20. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A.
Hua G; Liu Y; Li X; Xu P; Luo Y
Oncol Rep; 2014 Jun; 31(6):2727-34. PubMed ID: 24789077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
